|
An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer Clinical research trials and An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer. An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer clinical trial. Participants typically obtain the most effective healthcare available for their An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer  An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer
An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer
For Condition: Colonic Neoplasms,Colorectal Neoplasms
Status: Completed
Sponsor(s): Epimmune ,
Synopsis: EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Colon Cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Confirmed diagnosis of Colon Cancer, stage III - At least four weeks following prior standard treatment, with no evidence of disease - Must use adequate birth control Exclusion Criteria: - Prior cancer vaccine therapy or concurrent participation in any other investigational study - A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment - A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine - Women who are pregnant, intend to become pregnant, or who are breast feeding
Total Enrollment: 18
Location and Contact Information:
University of Southern California School of Medicine
Los Angeles, California, 90033
United States
Cancer Centers of Florida
Orlando, Florida, 32806
United States
University of California, San Diego
San Diego, California, 92037
United States
New York Oncology Hematology
Albany, New York, 12208
United States
University of Washington
Seattle, Washington, 91895
United States
Tyler Cancer Center
Tyler, Texas, 75702
United States
Duke University Medical Center
Durham, North Carolina, 27710
United States
Cancer Care Northwest
Spokane, Washington, 99218
United States
Mary Crowley Medical Research Center
Dallas, Texas, 75246
United States
Additional Information:
Study ID Numbers: EP2101-102;
Study Start Date: February 2003
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00054912
Other Colorectal Neoplasms Studies:
1. EPO906 Therapy in Patients with Advanced Colorectal Cancer
2. First-line treatment of metastatic colorectal cancer with oxaliplatin/5-FU/leucovorin plus PTK787/ZK 222584 or placebo
3. A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
4. An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer
5. Treatment of patients with previously treated metastatic colorectal cancer with oxaliplatin/5FU/LV and PTK787 or placebo
Related Studies:
Other Colorectal Neoplasms Clinical Trials
Other Texas Clinical Trials
Other Dallas Clinical Trials
An Open Label Study of a Peptide Vaccine in Patients with Stage III Colon Cancer
|
|
|
|
|
|
|
|
